RxDoctor Payments Data

Geetha Kandimala, MD

Clinical Neurophysiology · Norman, OKNPI 1922200435

Payments from drug & device makers

$36,809in general payments, 2019–2025

Across 939 payments — averaging $39.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Livanova USA, Inc.$2K
  • Medtronic$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$914
  • Novartis$862
  • plus $10K from 43 others

What the payments were for

  • Speaking & faculty fees$17,96549%
  • Travel & lodging$2,5267%
  • Food & beverage$16,05444%
  • Education$2641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$308,372
Medicare patients
974
Services billed
8,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab22$196,942
AustedoDeutetrabenazine24$156,191
NuplazidPimavanserin Tartrate22$108,811
NeuproRotigotine51$64,907
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$46,552
UbrelvyUbrogepant35$46,298
Aimovig AutoinjectorErenumab-Aooe46$44,970
AptiomEslicarbazepine Acetate19$39,745
Emgality PenGalcanezumab-Gnlm53$36,025
BriviactBrivaracetam16$31,613
BotoxOnabotulinumtoxina14$29,766
Lacosamide185$27,636
GlatopaGlatiramer Acetate11$26,965
QuliptaAtogepant16$19,624
Trokendi XrTopiramate19$18,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,094$156,19124 claims
Acadia Pharmaceuticals IncNuplazid$390$108,81122 claims
UCB, Inc.Neupro, Briviact$914$96,52167 claims
AbbVieUbrelvy, Botox, Qulipta$20,829$95,68865 claims
Sunovion Pharmaceuticals Inc.Aptiom$345$39,74519 claims
PfizerEliquis, Nurtec Odt$248$29,00331 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$450$18,24319 claims
SK Life Science, Inc.Xcopri$854$13,60012 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$151$5,39434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Norman

Where these figures come from

Is this you, or does something look wrong? →